Paytm posts first-ever profit of Rs 122.5 crore in Q1 FY26
Paytm had posted a net loss of Rs 840 crore in the year-ago period.
New Delhi, Jul 22 (PTI) Fintech firm One97 Communications, which owns the Paytm brand, reported its first-ever consolidated net profit at Rs 122.5 crore in the quarter ended June 2025, mainly on account of cost optimisation and an increase in payment revenue.
The company slashed marketing and promotional expenses by more than half to Rs 99.8 crore during the reported quarter from Rs 221.4 crore a year ago and Rs 142.7 crore in the March 2025 quarter.
Paytm reduced employee benefits by about Rs 300 crore or one-third to about Rs 643 crore from Rs 952.5 crore on a year-over-year basis.
While the company increased sales employee cost by 19 per cent on a YoY basis to Rs 266 crore, it recorded a reduction in non-sales employee cost by 28 per cent YoY to Rs 346 crore due to the use of artificial intelligence in various processes across its business.
Paytm's average number of sales employees increased by 23 per cent YoY basis to 38,945.
The consolidated revenue from operations in the reporting quarter increased by about 28 per cent to Rs 1,917.5 crore from Rs 1,501.6 crore in the June 2024 quarter mainly on account of an increase in payment processing margins.
'In the first quarter of FY'25, payment services revenue (including other operating revenue) was up 23 per cent YoY at Rs 1,110 crore. Net payment revenue was up 38 per cent YoY at Rs 529 crore due to an increase in payment processing margin and device,' the company said.
Paytm reported 27 per cent YoY increase in gross merchandise value to Rs 5.39 lakh crore in the reported quarter.
The company said that merchant subscriptions were at an all-time high of 1.3 crore, an increase of 21 lakh YoY, on the back of high-quality devices and superior service network as of June 2025.
'To further strengthen tier-1 market position and expand in tier-2 and tier-3 cities, we are investing in expanding our sales network (sales people costs are up 19 per cent YoY),' the statement said.
During the reported quarter, Paytm said that average monthly transacting users (MTU) base reached 7.4 crore.
The company said that distribution of financial services revenue grew 100 per cent YoY to Rs 561 crore, driven by continued expansion in merchant loans, trail revenue from Default Loss Guarantee (DLG) portfolio, and improvement in asset quality.
Paytm reported an 88 per cent decline in ESOP (employee stock ownership plan) costs to Rs 30 crore from Rs 169 crore in the March quarter and Rs 247 crore a year ago.
The company had made ESOP cost related adjustments in the March quarter when its CEO Vijay Shekhar Sharma voluntarily surrendered his ESOPs. PTI PRS PRS MR MR
This report is auto-generated from PTI news service. ThePrint holds no responsibility for its content.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
India.com
12 minutes ago
- India.com
India's Pharma Exports Have Shot Up By 92% In Last 6 Years: Minister
New Delhi: Various schemes being implemented by the Centre to realise the vision of Aatmanirbhar Bharat in the pharmaceutical sector have resulted in India's exports of drugs and pharmaceuticals increasing by 92 per cent, from Rs 1,28,028 crore in FY2018-19 to Rs 2,45,962 crore in FY2024-25, the Parliament was informed on Friday. The schemes include the Promotion of Research and Innovation in Pharma MedTech Sector (PRIP) scheme, the Production Linked Incentive (PLI) Scheme for Pharmaceuticals, the PLI Scheme for Bulk Drugs, Scheme for Promotion of Bulk Drug Parks, and Strengthening of Pharmaceutical Industry scheme, Minister of State for Chemicals and Fertilisers Anupriya Patel told the Lok Sabha in a written reply to a question. The PRIP scheme has been launched with an outlay of Rs 5,000 crore to transform India's Pharma MedTech sector from cost- to innovation-based growth by strengthening research and promoting industry-academia linkage for research and development in priority areas in drug discovery and development and medical devices. Under this scheme, seven Centres of Excellence (CoEs) have been set up, she said. The PLI Scheme for Pharmaceuticals aims to enhance India's manufacturing capabilities by increasing investment and production in the sector and contributing to product diversification to high-value goods in the pharmaceutical sector. The minister said that the scheme has enabled enhanced investment and production in eligible products. As of March 2025, the committed investment of Rs 17,275 crore targeted over the six-year period of the scheme stands substantially exceeded with a cumulative investment of Rs 37,306 crore made by the scheme's third year, and cumulative sales of approved products of Rs 2,66,528 crore have been made, including exports of Rs 1,70,807 crore. The PLI Scheme for Bulk Drugs, which has a total budgetary outlay of Rs 6,940 crore, aims to avoid disruption in the supply of critical active pharmaceutical ingredients (APIs) used to make critical drugs for which there are no alternatives by reducing supply disruption risk due to excessive dependence on a single source. As of March 2025, the committed investment of Rs 3,938.5 crore under projects approved under the scheme for investment over the six-year production period of the scheme stands substantially exceeded with a cumulative investment of Rs 4,570 crore made by the scheme's third year, she further stated. The minister also highlighted that the government launched the Pradhan Mantri Bhartiya Janaushadhi Pariyojana scheme to make quality generic medicines available at affordable prices to all. Under the scheme, dedicated outlets known as Jan Aushadhi Kendras (JAKs) are opened across the country to provide medicines at prices that are about 50 per cent to 80 per cent lower than those of leading branded medicines in the market. Till June 6, 2025, a total of 16,912 JAKs have been opened, and on average, about 10 to 12 lakh persons visit these Kendras daily and avail of quality medicines at affordable prices. As many as 2,110 medicines and 315 surgicals, medical consumables and devices are under the scheme product basket, covering all major therapeutic groups, such as cardiovascular, anti-cancer, anti-diabetic, anti-infectives, anti-allergic and gastro-intestinal medicines and nutraceuticals. As a result of the scheme, in the last 11 years, estimated savings of about Rs 38,000 crore have accrued to citizens in comparison to the prices of branded medicines. Further, the scheme has provided self-employment to over 16,000 persons, including over 6,800 women entrepreneurs, the minister added.
News18
19 minutes ago
- News18
Hyundai India Gets Rs 517.34 Cr Tax With Penalty Demand From GST Authority, Here's Why
Last Updated: The company said there is no impact on its financial, operational or other activities due to the order and is reviewing the order and will exercise the right to file an appeal. Hyundai Motor India Ltd on Tuesday said it has received a demand of Rs 517.34 crore from tax authorities, along with penalty, for alleged short payment of GST compensation cess on its certain SUV models. The company has received an order from Commissioner (Appeals), CGST Dept, Tamil Nadu, confirming GST compensation cess demand of Rs 258.67 crore, along with penalty of Rs 258.67 crore, on the allegation of short payment of GST compensation cess on certain SUV models for the period September 2017 – March 2020, Hyundai Motor India Ltd said in a regulatory filing. Reacting to the demand, a company spokesperson said, 'HMIL is of the view that the amendment and the clarifications given by the Central Board of Indirect Tax and Customs (CBIC) to resolve the issue faced by the industry on this matter are in favour of the company. We are in the process of reviewing the order and will exercise the right to seek a legal remedy through an appropriate forum." The company asserted that there is no impact on its financial, operational or other activities due to the order and is reviewing the order and will exercise the right to file an appeal. . view comments First Published: July 26, 2025, 08:17 IST Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
Time of India
24 minutes ago
- Time of India
Atal Pension Yojana enrolments cross 8 crore mark; adds 39 lakh new subscribers so far in FY26
Social Security scheme Atal Pension Yojana has crossed 8 crore total gross enrolments, with an addition of 39 lakh new subscribers so far in the current fiscal, the Finance Ministry said on Friday. APY was launched on May 9, 2015. Explore courses from Top Institutes in Please select course: Select a Course Category Technology others Digital Marketing MBA Operations Management Healthcare MCA healthcare Data Analytics Management Cybersecurity Finance Leadership Others Project Management PGDM Public Policy Data Science Artificial Intelligence CXO Design Thinking Product Management Degree Data Science Skills you'll gain: Duration: 12 Weeks MIT xPRO CERT-MIT XPRO Building AI Prod India Starts on undefined Get Details "The Atal Pension Yojana (APY), a flagship social security scheme of the Government of India administered by PFRDA , has achieved a significant milestone by surpassing 8 crore total gross enrolments with an addition of 39 lakh new subscribers in the current Financial Year (FY 2025-26) alone," the ministry said in a statement. Launched with a vision to create a universal social security system for all Indians, APY is a voluntary, contributory pension scheme , focused on the poor, the underprivileged, and workers in the unorganised sector. APY assures a guaranteed monthly pension of Rs 1,000 to Rs 5,000 for the subscriber post-60 years of age, the same pension to the spouse after the subscriber's demise, and return of the accumulated corpus to the nominee after the death of both. It is open to all Indian citizens between the age of 18-40 years, except those who are or have been income tax payers.
